Yuyu Pharma Inc (000227) - Total Liabilities
Based on the latest financial reports, Yuyu Pharma Inc (000227) has total liabilities worth ₩63.32 Billion KRW (≈ $42.91 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 000227 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Yuyu Pharma Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Yuyu Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 000227 asset base.
Yuyu Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Yuyu Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Urban One Inc Class D
NASDAQ:UONEK
|
USA | $642.06 Million |
|
IFCA MSC Bhd
KLSE:0023
|
Malaysia | RM31.11 Million |
|
Tong-Hwa Synthetic Fiber Co Ltd
TW:1418
|
Taiwan | NT$4.10 Billion |
|
B&M European Value Retail SA
LSE:BME
|
UK | GBX3.17 Billion |
|
Apollomics Inc. Class A Ordinary Shares
NASDAQ:APLM
|
USA | $9.90 Million |
|
SBF AG
F:CY1K
|
Germany | €17.86 Million |
|
Tate & Lyle PLC
LSE:TATE
|
UK | GBX2.07 Billion |
|
Next Science Ltd
AU:NXS
|
Australia | AU$10.02 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Yuyu Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 000227 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yuyu Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yuyu Pharma Inc (2014–2024)
The table below shows the annual total liabilities of Yuyu Pharma Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩72.62 Billion ≈ $49.22 Million |
-6.72% |
| 2023-12-31 | ₩77.86 Billion ≈ $52.76 Million |
+8.39% |
| 2022-12-31 | ₩71.83 Billion ≈ $48.68 Million |
+11.71% |
| 2021-12-31 | ₩64.30 Billion ≈ $43.58 Million |
+69.82% |
| 2020-12-31 | ₩37.86 Billion ≈ $25.66 Million |
-19.73% |
| 2019-12-31 | ₩47.17 Billion ≈ $31.97 Million |
-2.44% |
| 2018-12-31 | ₩48.35 Billion ≈ $32.77 Million |
+25.08% |
| 2017-12-31 | ₩38.66 Billion ≈ $26.20 Million |
+17.11% |
| 2016-12-31 | ₩33.01 Billion ≈ $22.37 Million |
+7.88% |
| 2015-12-31 | ₩30.60 Billion ≈ $20.73 Million |
+2.29% |
| 2014-12-31 | ₩29.91 Billion ≈ $20.27 Million |
-- |
About Yuyu Pharma Inc
Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc.… Read more